30 August 2017
Visiongain’s new report the Global Electrophysiology Devices Market Forecast 2017-2026: Revenue Forecasts for Monitoring Devices (Including Echocardiography, Diagnostic Catheters, Holter Monitors and Event Monitors) and Treatment Devices (Including Pacemakers, ICDs, Ablation Catheters, CRT-Ds and CRT-Ps) indicates that the global electrophysiology market will see over $9.5bn in revenue in 2017.
The lead analyst of the report said:
“The electrophysiology market is expected to experience considerable growth over the forecast period. The main drivers for the growth include an increasingly ageing population, rising prevalence of cardiovascular diseases and growing patient awareness of electrophysiology treatments and products available. In patients suffering from regular arrhythmia, several implants have been developed and introduced to keep the heart rhythm in control. Atrial fibrillation is the most common type of arrhythmia .The number of patients suffering from Atrial fibrillation in US is approximately 2.5-6.1 million people, according to different sources and is expected to increase further. The risk of Atrial fibrillation increases with the age and high blood pressure. Atrial fibrillation is a moderate arrhythmia, sometimes leads to heart failure. In the US alone, around 750,000 hospitalizations occur due to Atrial fibrillation, contributing to approximately 130,000 deaths every year.
Increased incidence of cardiovascular diseases such as heart failure, stroke and arrhythmia will drive the electrophysiology devices market throughout the forecast period. The number of deaths caused due to these diseases is predicted to increase from 17.3 million in 2015 to 21.7 million in 2026.”
The 147 page report contains 103 tables, charts and graphs that add visual analysis in order to explain developing trends within the electrophysiology market. Visiongain provides revenue forecasts for the period 2017-2026 for the leading diagnostic and treatment device submarkets, namely Electrocardiography, Holter Monitoring Devices, Event Monitors, Diagnostic Catheters and X-ray systems. The report also includes forecasts for Ablation Catheters, Pacemakers, Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy Defibrillators (CRT-D), Cardiac Resynchronization Therapy Pacemakers (CRT-P) and Implantable Loop Recorders.
The 147 page report offers market forecasts and analysis for 11 leading national markets and the rest of the world market. In addition, the report contains a dedicated leading companies’ chapter covering more than 6 companies leading the field in electrophysiology devices.
The Global Electrophysiology Devices Market Forecast 2017-2026: Revenue Forecasts for Monitoring Devices (Including Echocardiography, Diagnostic Catheters, Holter Monitors and Event Monitors) and Treatment Devices (Including Pacemakers, ICDs, Ablation Catheters, CRT-Ds and CRT-Ps) report will be of value to anyone who wants to better understand the electrophysiology devices market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the electrophysiology device industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.